Board, committees and an organigram. How we are organized and who does what: learn more about us.
Oncode Institute operates with a small team to provide valorization services, general management and support to all the Oncode Researchers across the Partner Institutions. Oncode does not have its own research facilities or staff. Every Oncode Researcher is employed by one of the Partner Institutions, at which the actual research is conducted.
Oncode’s staff is guided and supported by its board and committees. The Oncode team and the members of the boards and committees perform their duties in awareness of their extraordinary responsibility to spend public funds in the most effective and efficient manner possible, to serve society and to set an example.
Oncode is founded on the assumption that everyone involved in the Institute is committed to constantly improving Oncode and its way of working. Oncode listens. Not only to its boards, committees and the Oncode team, but to all Oncode Researchers, partners and patients. Because all of us together know more than the few managing the Institute. If you have any questions or suggestions, please feel free to contact us at any time.
The members of the Managing Board operate and manage Oncode, taking into account that Oncode has an important social responsibility. The Managing Board consists of the Head of the Institute, Managing Director and a Valorization Director.
Oncode Investigator Geert Kops is the Head of the Institute and chair of the Research Management Committee of Oncode Institute. Geert Kops is group leader at the Hubrecht Institute and professor of Molecular Tumor Cell Biology at the University Medical Center Utrecht. His group studies the signaling networks that regulate chromosome segregation, the evolution of cell division processes and the role of chromosomal instability in cancer.
"Synergy between Oncode researchers will create even more breakthrough discoveries, also towards the clinic.”
Alain Kummer is Managing Director of the Oncode Institute since the beginning of September 2020. Alain has a wealth of experience in different healthcare disciplines. In the past, Alain has worked as a clinical and molecular pathologist and managed his own research group on tumour immunology. He improved patient care by initiating and leading biomedical facilities. He holds an MBA degree and was involved as an interim CEO during the merger of two organizations. Before becoming Managing Director of Oncode, Alain was involved in the scouting and selection of early health care innovations and acted as venture partner for several start-ups.
Chris De Jonghe joined Oncode Institute since June 2020 as our Valorization Director. Chris has a multi-disciplinary experience in the life sciences sector. She was trained as a biochemist and obtained a PhD in the field of neurodegeneration. In addition, she holds a law degree. She was active for more than 12 years in technology transfer at the VIB (Flanders’ Institute for Biotechnology) in Belgium. Subsequently she managed a 200 M€ evergreen VC fund at PMV (ParticipatieMaatschappij Vlaanderen). She was in that capacity board member in several innovative life sciences companies, investment funds and cluster organizations.
To ensure good governance, Oncode has developed its Good Governance Charter based on the rules in the Dutch Corporate Governance Code and the Good Governance Code for charities (SBF-Code Goed Bestuur).
The Good Governance Charter constitutes the regulations of Oncode’s most prominent and influential boards and committees, and also comprehends key policies. Please find the Good Governance Charter here. Please note that the Good Governance Charter is still work in progress and will be finalized soon.
Oncode Institute is a foundation. Please find Oncode’s articles of association here.
Please find Oncode on the ANBI website.